John Renger - 23 Dec 2021 Form 4 Insider Report for Cerevel Therapeutics Holdings, Inc. (CERE)

Role
Chief Scientific Officer
Signature
/s/ Mark Bodenrader, as Attorney-in-Fact
Issuer symbol
CERE
Transactions as of
23 Dec 2021
Transactions value $
-$315,027
Form type
4
Filing time
28 Dec 2021, 15:31:01 UTC
Previous filing
23 Dec 2021
Next filing
11 Feb 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CERE Common Stock Options Exercise $20.6K +5.87K +296.62% $3.50* 7.85K 23 Dec 2021 Direct F1, F2
transaction CERE Common Stock Sale -$206K -5.87K -74.79% $35.00 1.98K 23 Dec 2021 Direct F1, F3
transaction CERE Common Stock Options Exercise $14.4K +4.13K +208.43% $3.50* 6.11K 27 Dec 2021 Direct F1
transaction CERE Common Stock Sale -$144K -4.13K -67.58% $35.00 1.98K 27 Dec 2021 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CERE Stock Option (Right to Buy) Options Exercise $0 -5.87K -1.54% $0.00 375K 23 Dec 2021 Common Stock 5.87K $3.50 Direct F1, F4
transaction CERE Stock Option (Right to Buy) Options Exercise $0 -4.13K -1.1% $0.00 371K 27 Dec 2021 Common Stock 4.13K $3.50 Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan dated October 8, 2021 adopted by the Reporting Person.
F2 Includes 1,980 shares acquired under the Issuer's Employee Stock Purchase Plan on May 28, 2021.
F3 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.00 to $35.01 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or to the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4 25% of the shares subject to this option vested and became exercisable on April 8, 2020, with the remainder vesting in thirty-six (36) equal monthly installments thereafter.